CN110831975A - 用于治疗神经退行性疾病的cd14拮抗剂抗体 - Google Patents

用于治疗神经退行性疾病的cd14拮抗剂抗体 Download PDF

Info

Publication number
CN110831975A
CN110831975A CN201880040765.4A CN201880040765A CN110831975A CN 110831975 A CN110831975 A CN 110831975A CN 201880040765 A CN201880040765 A CN 201880040765A CN 110831975 A CN110831975 A CN 110831975A
Authority
CN
China
Prior art keywords
antibody
sequence
domain
cdr1
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880040765.4A
Other languages
English (en)
Chinese (zh)
Inventor
加里·卢埃林·雷德里希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Implicit Bioscience Ltd
Original Assignee
Implicit Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017901462A external-priority patent/AU2017901462A0/en
Application filed by Implicit Bioscience Ltd filed Critical Implicit Bioscience Ltd
Publication of CN110831975A publication Critical patent/CN110831975A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880040765.4A 2017-04-21 2018-04-20 用于治疗神经退行性疾病的cd14拮抗剂抗体 Pending CN110831975A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2017901462 2017-04-21
AU2017901462A AU2017901462A0 (en) 2017-04-21 Agents for treating or preventing motor neurone disease and uses therefor
AU2018900762 2018-03-08
AU2018900762A AU2018900762A0 (en) 2018-03-08 “agents for treating disease and uses therefor”
PCT/AU2018/050357 WO2018191786A1 (en) 2017-04-21 2018-04-20 Cd 14 antagonist antibodies for treating neurodegenerative diseases

Publications (1)

Publication Number Publication Date
CN110831975A true CN110831975A (zh) 2020-02-21

Family

ID=63855469

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880040765.4A Pending CN110831975A (zh) 2017-04-21 2018-04-20 用于治疗神经退行性疾病的cd14拮抗剂抗体

Country Status (8)

Country Link
US (2) US20200148780A1 (https=)
EP (1) EP3612566A4 (https=)
JP (2) JP2020517740A (https=)
KR (1) KR20200015477A (https=)
CN (1) CN110831975A (https=)
AU (1) AU2018255489B2 (https=)
IL (2) IL309046B2 (https=)
WO (1) WO2018191786A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116367858A (zh) * 2020-09-10 2023-06-30 隐式生物科技有限公司 用于治疗心肌梗塞的治疗方法和试剂
CN117031014A (zh) * 2023-08-14 2023-11-10 陕西脉元生物科技有限公司 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒
CN120399098A (zh) * 2025-07-03 2025-08-01 上海玄言生物科技有限公司 抗cd14抗体-il-15超级激动剂融合蛋白及其制法和应用

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019264996A1 (en) * 2018-05-10 2020-11-26 The Methodist Hospital Methods for prognosis and management of disease
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
US20200392229A1 (en) * 2019-06-11 2020-12-17 Alector Llc Methods of use of anti-sortilin antibodies
WO2021016601A1 (en) 2019-07-25 2021-01-28 Implicit Bioscience Limited Methods and agents for treating acute neuroinflammatory injury
MX2022010006A (es) * 2020-02-13 2022-09-19 Prilenia Neurotherapeutics Ltd Terapia combinada para el tratamiento de la amiotrofica lateral con pridopidina y otro agente activo.
WO2021253335A1 (zh) * 2020-06-18 2021-12-23 深圳迈瑞生物医疗电子股份有限公司 抗可溶性cd14亚型抗体、试剂盒及其应用
AU2021356298A1 (en) 2020-10-07 2023-05-04 Line 6 Biotechnology, Inc Methods and agents for the treatment of ocular disease
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN118290585B (zh) * 2024-06-04 2024-08-30 苏州为度生物技术有限公司天津分公司 一种抗人cd14工程抗体及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820858A (en) * 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
US20090181008A1 (en) * 2005-11-10 2009-07-16 Satoris, Inc. Methods of treating alzheimer's disease
CN102869680A (zh) * 2010-02-26 2013-01-09 生命北极神经科学公司 原细纤维结合抗体及其在帕金森氏症、路易体痴呆和其他α-共核蛋白病的治疗和诊断方法中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI920450A7 (fi) * 1989-08-01 1992-01-31 Scripps Clinic And Res Foundation Menetelmiä ja koostumuksia verenmyrkytyksen oireiden estämiseksi
EP0792162B1 (en) * 1994-09-16 2005-11-09 The Scripps Research Institute Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
US7264967B2 (en) 2000-11-22 2007-09-04 Mochida Pharmaceutical Co., Ltd. Anti-CD14 monoclonal antibody having effect of inhibiting CD14/TLR binding
EP1819829A1 (en) 2004-12-08 2007-08-22 ICOS Corporation Recombinant method for making multimeric proteins
KR101256837B1 (ko) * 2009-03-09 2013-04-22 경북대학교 산학협력단 가용성 ｃｄ１４의 파킨슨 병 진단 및 치료용 용도
WO2018165720A1 (en) * 2017-03-17 2018-09-20 Implicit Bioscience Pty Ltd Agents for treating or preventing viral infections and uses therefor
AU2019264996A1 (en) * 2018-05-10 2020-11-26 The Methodist Hospital Methods for prognosis and management of disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820858A (en) * 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
US20090181008A1 (en) * 2005-11-10 2009-07-16 Satoris, Inc. Methods of treating alzheimer's disease
CN102869680A (zh) * 2010-02-26 2013-01-09 生命北极神经科学公司 原细纤维结合抗体及其在帕金森氏症、路易体痴呆和其他α-共核蛋白病的治疗和诊断方法中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
S.H. APPEL等: "The Microglial-Motoneuron dialogue in ALS", 《ACTA MYOLOGICA》 *
WEIHUA ZHAO等: "TDP-43 activates microglia through NF-κB and NLRP3 inflammasome", 《EXPERIMENTAL NEUROLOGY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116367858A (zh) * 2020-09-10 2023-06-30 隐式生物科技有限公司 用于治疗心肌梗塞的治疗方法和试剂
CN117031014A (zh) * 2023-08-14 2023-11-10 陕西脉元生物科技有限公司 抗matr3自身抗体的试剂在制备检测神经系统自身免疫疾病的产品中的应用及试剂盒
CN120399098A (zh) * 2025-07-03 2025-08-01 上海玄言生物科技有限公司 抗cd14抗体-il-15超级激动剂融合蛋白及其制法和应用
CN120399098B (zh) * 2025-07-03 2025-09-16 上海玄言生物科技有限公司 抗cd14抗体-il-15超级激动剂融合蛋白及其制法和应用

Also Published As

Publication number Publication date
US12297287B2 (en) 2025-05-13
IL309046B1 (en) 2024-11-01
IL309046B2 (en) 2025-03-01
WO2018191786A1 (en) 2018-10-25
IL270097B1 (en) 2024-01-01
US20200148780A1 (en) 2020-05-14
US20220010025A1 (en) 2022-01-13
JP2020517740A (ja) 2020-06-18
IL270097A (https=) 2019-12-31
AU2018255489A1 (en) 2019-11-07
EP3612566A1 (en) 2020-02-26
IL309046A (en) 2024-02-01
KR20200015477A (ko) 2020-02-12
AU2018255489B2 (en) 2024-06-13
EP3612566A4 (en) 2021-03-03
IL270097B2 (en) 2024-05-01
JP2023090751A (ja) 2023-06-29

Similar Documents

Publication Publication Date Title
US12297287B2 (en) CD14 antagonist antibodies for treating neurodegenerative diseases
JP7730936B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
JP7554247B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
JP2024009818A (ja) 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
KR20230005848A (ko) 항-trem2 항체의 사용 방법
KR20210025614A (ko) 항-sirp-베타1 항체 및 그의 사용 방법
KR20230116850A (ko) Trem2　작용제 바이오마커 및 이의 사용 방법
EP3082863B1 (en) Alpha-enolase specific antibodies and method of use in immune diseases
TW202241945A (zh) 類固醇節制
HK40101643A (en) Anti-trem2 antibodies and methods of use thereof
HK40087465A (zh) 抗trem2抗体的使用方法
EA044134B1 (ru) Анти-trem2 антитела и способы их применения
HK40019817A (en) Anti-trem2 antibodies and methods of use thereof
HK40019817B (en) Anti-trem2 antibodies and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Queensland, Australia

Applicant after: Inprecit bioscience Co.,Ltd.

Address before: Queensland, Australia

Applicant before: Inplicit Biosciences Pte. Ltd.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200221